|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/11/22 Aveanna Healthcare Holdings, Inc. 10-Q 7/02/22 69:9.6M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 3.52M
2: EX-10.1 Material Contract HTML 87K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
12: R1 Document and Entity Information HTML 72K
13: R2 Consolidated Balance Sheets HTML 141K
14: R3 Consolidated Balance Sheets (Parenthetical) HTML 40K
15: R4 Consolidated Statements of Operations (Unaudited) HTML 97K
16: R5 Consolidated Statements of Stockholders' Equity HTML 62K
17: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 142K
18: R7 Description of Business HTML 25K
19: R8 Summary of Significant Accounting Policies HTML 32K
20: R9 Revenue HTML 83K
21: R10 Goodwill HTML 72K
22: R11 Long-Term Obligations HTML 90K
23: R12 Securitization Facility HTML 32K
24: R13 Fair Value Measurements HTML 77K
25: R14 Derivative Financial Instruments HTML 63K
26: R15 Income Taxes HTML 32K
27: R16 Share-Based Compensation HTML 55K
28: R17 Commitments and Contingencies HTML 51K
29: R18 Covid-19 HTML 45K
30: R19 Related Party Transactions HTML 27K
31: R20 Segment Information HTML 243K
32: R21 Net (Loss) Income Per Share HTML 93K
33: R22 Subsequent Events HTML 27K
34: R23 Summary of Significant Accounting Policies HTML 39K
(Policies)
35: R24 Revenue (Tables) HTML 68K
36: R25 Goodwill (Tables) HTML 68K
37: R26 Long-Term Obligations (Tables) HTML 71K
38: R27 Fair Value Measurements (Tables) HTML 73K
39: R28 Derivative Financial Instruments (Tables) HTML 51K
40: R29 Segment Information (Tables) HTML 236K
41: R30 Net (Loss) Income Per Share (Tables) HTML 92K
42: R31 Description of Business - Additional Information HTML 21K
(Details)
43: R32 Revenue - Additional Information (Detail) HTML 28K
44: R33 Revenue - Schedule of Revenue by Payer Type as a HTML 37K
Percentage of Revenue (Detail)
45: R34 Goodwill - Summary of Changes in Goodwill by HTML 38K
Segment (Details)
46: R35 Goodwill - Summary of Changes in Goodwill by HTML 28K
Segment (Parenthetical) (Details)
47: R36 Goodwill - Additional Information (Details) HTML 29K
48: R37 Long-Term Obligations - Schedule of Long-Term HTML 55K
Obligations and Notes Payable (Details)
49: R38 Long-Term Obligations - Schedule of Long-Term HTML 27K
Obligations and Notes Payable (Parenthetical)
(Details)
50: R39 Long-Term Obligations - Additional Information HTML 79K
(Details)
51: R40 Securitization Facility - Additional Information HTML 38K
(Details)
52: R41 Fair Value Measurements - Summary of Other Assets HTML 37K
and Other Liabilities Measured at Fair Value
(Details)
53: R42 Derivative Financial Instruments - Additional HTML 51K
Information (Details)
54: R43 Derivative Financial Instruments - Schedule of HTML 29K
Gains from Derivatives (Details)
55: R44 Income Taxes - Additional Information (Detail) HTML 29K
56: R45 Share-Based Compensation - Additional Information HTML 68K
(Details)
57: R46 Commitments and Contingencies - Additional HTML 60K
Information (Details)
58: R47 Covid-19 - Additional Information (Detail) HTML 63K
59: R48 Related Party Transactions - Additional HTML 28K
Information (Details)
60: R49 Segment Information - Additional Information HTML 24K
(Details)
61: R50 Segment Information - Summary of Segment HTML 48K
Information (Details)
62: R51 Segment Information - Summary of Segment HTML 61K
Reconciliation (Details)
63: R52 Net (Loss) Income Per Share - Summary of HTML 62K
Computation of Basic and Diluted Net (Loss) Income
Per Share (Detail)
64: R53 Subsequent Events - Additional Information HTML 31K
(Details)
67: XML IDEA XML File -- Filing Summary XML 120K
65: XML XBRL Instance -- avah-20220702_htm XML 2.01M
66: EXCEL IDEA Workbook of Financial Reports XLSX 118K
7: EX-101.CAL XBRL Calculations -- avah-20220702_cal XML 154K
10: EX-101.DEF XBRL Definitions -- avah-20220702_def XML 485K
11: EX-101.LAB XBRL Labels -- avah-20220702_lab XML 1.07M
8: EX-101.PRE XBRL Presentations -- avah-20220702_pre XML 773K
9: EX-101.SCH XBRL Schema -- avah-20220702 XSD 146K
68: JSON XBRL Instance as JSON Data -- MetaLinks 348± 532K
69: ZIP XBRL Zipped Folder -- 0000950170-22-016576-xbrl Zip 382K
| EX-31.2 |
Exhibit 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, David Afshar, certify that:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 10, 2022 |
By: |
/s/ David Afshar |
|
|
|
|
|
Chief Financial Officer (Principal Financial and Accounting Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 8/11/22 | 8-K | ||
| Filed on: | 8/10/22 | 8-K | ||
| For Period end: | 7/2/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/14/24 Aveanna Healthcare Holdings, Inc. 10-K 12/30/23 106:14M Donnelley … Solutions/FA 3/16/23 Aveanna Healthcare Holdings, Inc. 10-K 12/31/22 108:17M Donnelley … Solutions/FA |